AN2 Therapeutics, Inc. (ANTX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XHAM Summary
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
AN2 Therapeutics (ANTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
3 Penny Stocks To Buy With Just $750
Anyone with any experience as an investor knows that while penny stocks can produce strong returns, they're also risky.
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.
AN2 Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 2,600 | $8,892 | $11,934 | $3,042 | 34.21% |
| PLC Peapod Lane Capital LLC Peapod Lane Capital LLC | 59,854 | $80,232.48 | $283,707.96 | $203,475.48 | 253.61% |
 Yuen Man Lee Persistent Asset Partners Ltd. | 38,155 | $130,490 | $178,374.62 | $47,884.62 | 36.7% |
AN2 Therapeutics, Inc. (ANTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has AN2 Therapeutics, Inc. ever had a stock split?
AN2 Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Eric E. Easom CEO | NASDAQ (NGS) Exchange | 037326105 CUSIP |
| US Country | 21 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a focused mission to develop treatments for rare, chronic, and serious infectious diseases. Established in 2017 and based in Menlo Park, California, AN2 Therapeutics leverages its expertise in drug development to address unmet medical needs, particularly in the domain of infectious diseases that pose significant challenges to patient health. The company's dedication to innovation is underscored by its strategic licensing agreements, such as those with Anacor Pharmaceuticals, Inc. and Brii Biosciences Limited. These partnerships empower AN2 Therapeutics to broaden its therapeutic reach, enabling the advancement of its leading compounds, including epetraborole, in key markets like China, Hong Kong, Taiwan, and Macau, alongside its global aspirations.
Products and Services
- Epetraborole
- AN2-502998 (AN15368)
Epetraborole stands out as AN2 Therapeutics' flagship investigational drug, currently in the pivotal Phase 2/3 clinical trial stage. It is designed as a once-daily oral treatment targeting patients suffering from non-tuberculous mycobacterial lung disease, a condition that presents considerable treatment challenges due to its chronic nature and the limited effectiveness of current therapies. Rooted in AN2 Therapeutics' proprietary research and development, epetraborole represents a beacon of hope for patients in dire need of new treatment options.
This investigational boron-based small molecule is another testament to AN2 Therapeutics' commitment to addressing infectious diseases with innovative solutions. Currently in the preclinical trial phase, AN2-502998 (AN15368) is being developed to tackle chronic Chagas disease, a neglected tropical disease that continues to affect millions of people worldwide, primarily in Latin America. With its unique approach and potential for efficacy, AN2-502998 offers a promising avenue for combatting Chagas disease.
